Subscribe for great stories in your community!
GlaxoSmithKline has agreed to pay up to $61 million to license, research, and develop a cancer treatment based on Adaptimmune Therapeutics’ T-cell therapy, writes…
Before we send you to this site, please subscribe to our daily newsletter.